



Solenio Therapeutics to Participate in Upcoming November Investor Conferences

October 28, 2024 12:00 PM EDT

REDWOOD CITY, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Solenio") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will participate in the following upcoming investor conferences:

Event: Guggenheim Healthcare Innovation Conference

Date: Monday, November 11, 2024

Time: 10:00 AM ET

Event: Stifel 2024 Healthcare Conference

Date: Monday, November 18, 2024

Time: 4:45 PM ET

Event: Jefferies London Healthcare Conference

Date: Wednesday, November 20, 2024

Time: 8:00 AM GT

A live audio webcast and replay of the Guggenheim and Jefferies events will be available in the Investors section on the Company's website at www.solenio.life.

About Soleno Therapeutics, Inc.

Solenio is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company recently submitted an NDA to the FDA, supported by its Phase 3 development program, for its lead candidate, DCCR (diazoxide choline) extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS). For more information, please visit www.solenio.life.

Corporate Contact:

Brian Ritchie
LifeSci Advisors, LLC
212-915-2578



Source: Soleno Therapeutics